Corporate Sustainability Report

Overview

The report covers Neurocrine's 2022 ESG performance across patients and products, people, communities, environment and integrity. It describes Board and Nominating & Corporate Governance Committee oversight and reports against SASB and TCFD frameworks. Highlights include DE&I programs, supply-chain risk work, a new environmentally designed campus, and 94.4% hazardous-waste recycling. The report also describes product quality and clinical-trial transparency initiatives.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2022
Publication date: 1 June 2023
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services